Capricor Therapeutics Inc
CAPR6.400USD
+0.320+5.26%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
292.56MMarket Cap
LossP/E TTM
More Details of Capricor Therapeutics Inc Company
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.
Company Info
Ticker SymbolCAPR
Company nameCapricor Therapeutics Inc
IPO dateJun 04, 2002
CEODr. Linda Marban, Ph.D.
Number of employees160
Security typeOrdinary Share
Fiscal year-endJun 04
Address10865 Road to the Cure
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92121
Phone13103583200
Websitehttps://capricor.com/
Ticker SymbolCAPR
IPO dateJun 04, 2002
CEODr. Linda Marban, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
+6.26%
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
8.22K
+43.68%
Dr. Michael Binks, M.D.
Dr. Michael Binks, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Dr. Paul Auwaerter, M.D.
Dr. Paul Auwaerter, M.D.
Independent Director
Independent Director
--
--
Ms. Karimah Es Sabar
Ms. Karimah Es Sabar
Independent Director
Independent Director
--
--
Ms. Karen G. Krasney, J.D.
Ms. Karen G. Krasney, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
+6.26%
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
8.22K
+43.68%
Dr. Michael Binks, M.D.
Dr. Michael Binks, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nippon Shinyaku Co Ltd
15.51%
BlackRock Institutional Trust Company, N.A.
5.96%
The Vanguard Group, Inc.
5.02%
State Street Global Advisors (US)
3.21%
Geode Capital Management, L.L.C.
2.11%
Other
68.19%
Shareholders
Shareholders
Proportion
Nippon Shinyaku Co Ltd
15.51%
BlackRock Institutional Trust Company, N.A.
5.96%
The Vanguard Group, Inc.
5.02%
State Street Global Advisors (US)
3.21%
Geode Capital Management, L.L.C.
2.11%
Other
68.19%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.76%
Corporation
15.51%
Investment Advisor/Hedge Fund
8.60%
Hedge Fund
1.60%
Research Firm
1.47%
Individual Investor
1.28%
Bank and Trust
0.69%
Venture Capital
0.21%
Pension Fund
0.17%
Other
52.70%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
249
26.54M
58.06%
+1.05M
2025Q1
248
26.31M
57.59%
+1.55M
2024Q4
207
25.12M
55.44%
+10.37M
2024Q3
154
16.01M
37.60%
+3.34M
2024Q2
126
9.07M
28.24%
-1.39M
2024Q1
98
7.40M
24.60%
-337.42K
2023Q4
80
6.78M
23.62%
+312.08K
2023Q3
81
6.27M
24.30%
+2.56M
2023Q2
82
3.34M
13.02%
-283.03K
2023Q1
82
3.13M
12.44%
-2.22M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nippon Shinyaku Co Ltd
7.09M
15.51%
+4.94M
+230.41%
Sep 20, 2024
BlackRock Institutional Trust Company, N.A.
2.69M
5.89%
-69.04K
-2.50%
Mar 31, 2025
The Vanguard Group, Inc.
2.26M
4.94%
-12.79K
-0.56%
Mar 31, 2025
State Street Global Advisors (US)
1.84M
4.03%
-365.57K
-16.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
901.38K
1.97%
+21.91K
+2.49%
Mar 31, 2025
UBS Financial Services, Inc.
393.34K
0.86%
+270.52K
+220.26%
Mar 31, 2025
Morgan Stanley & Co. LLC
735.10K
1.61%
+164.73K
+28.88%
Mar 31, 2025
Pier Capital, LLC
354.18K
0.77%
+331.53K
+1463.51%
Mar 31, 2025
Northern Trust Investments, Inc.
368.07K
0.81%
-10.36K
-2.74%
Mar 31, 2025
Black Diamond Financial, LLC
277.74K
0.61%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
